EGFR and non-small cell lung carcinoma: Unlike lapatinib, the pan-ErbB inhibitor dacomitinib which has recently been FDA approved for non-small cell lung cancer,23,24 prevented HER2 protein synthesis, membrane localisation and eventual EGFR/HER2 heterodimerisation without compromising membrane integrity.